Xeris and Beta Bionics today announced an exclusive worldwide collaboration to develop a glucagon product for proprietary pump technology. The collaboration and license agreement covers the development and commercialization of a glucagon product utilizing the Xeris XeriSol technology. Xeris and Beta Bionics aim to utilize the product with proprietary bi-hormonal pump and pump systems. Glucagon, […]
Xeris Biopharma
Xeris Biopharma enters agreement for $30M private placement
Xeris Biopharma (NSDQ:XERS) announced today that it entered into a securities purchase agreement in connection with a private placement. Chicago-based Xeris’ private placement with an affiliate of Armistice Capital, LLC, will provide aggregate gross proceeds totaling approximately $30 million. The company will issue Armistice more than 10.2 million shares of its common stock at a […]
Xeris enters collaboration with Merck
Xeris Biopharma (NSDQ:XERS) announced today that it entered into a collaboration agreement with Merck (NYSE:MRK) for its XeriJect technology. Chicago-based Xeris’ collaboration with Merck includes an option to license the XeriJect suspension-based formulation technology for use with undisclosed monoclonal antibodies (mAbs) for the purpose of engineering ultra-high concentration, ready-to-use formulations. The financial terms of the […]
